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Introduction
Beta-thalassemias (β-thal) are inherited quantitative disorders of
haemoglobin (Hb) leading to underproduction of the beta globin
chains of hemoglobin. In β-thal, the synthesis of normal α globin
chains from the unaffected α globin gene continues as normal,
resulting in the accumulation within the erythroid precursors of excess
free α globin chains, which precipitate in the red cell precursors in the
bone marrow forming inclusion bodies. Excess free alpha globin chain
precipitate as insoluble hemichrome on the inner surface of red cell
membrane (membrane-bound), forming inclusions called micro-
Heinz bodies or occure as free cytosolic (soluble) hemichrome [1].
Among other names (free alpha hemoglobin, hemoglobin subunit
alpha, alpha-globin, alpha-1 globin, alpha-2 globin, unbound alpha
globin chain, free alpha globin chain, free alpha haemoglobin chain,
hemoglobin alpha-1 chain and hemoglobin alpha 1 globin), free alpha
haemoglobin (free α-Hb) is the preferred name [2,3]. A small but
reproducibly detectable, excess of α-globin mRNA is present in
normal erythroblasts in β-thal. However, β-globin mRNA is translated
more efficiently than α-globin mRNA. These counterbalancing forces
result in approximately equal synthesis of α- and β-globin polypeptide
chains. In normal reticulocytes, α-and β-globin chains production is
synchronous, though there is a very small excess of alpha chain
synthesis [3]. The pathophysiology of β-thal is the consequences of the
accumulation of excess, free α-Hb in erythroid precursors in bone
marrow and peripheral red blood cells forming inclusion bodies
abundant enough to be visible by light microscope in red cells
precursors and mature forms. The severity of β-thal is mainly
correlates with the extent of imbalance between α- and non-α-globin
chains and the amount of the free α-Hb pool in the erythrocytes rather
than the underproduction of Hb. The erythroid cells capacity to
detoxify and remove the damaging α-Hb inclusions protein via quality
control pathway are exceeded in red cells of individual with severe
forms of β-thal [4]. The major problem in β-thal is accumulation of
excess free globin chains (α-Hb) in the erythrocytes precursors in the
bone marrow and peripheral erythrocytes forming inclusion bodies,
thus, patients with β0 thalassemia is clinically worse than patients with
β+ thalassemia, and there is a general trend in this direction [5,6]. In
β-thal trait there is a two-fold increase in the synthesis of alpha globin
and the ratio of alpha to non-alpha globin in individual with β-thal
intermedia is three to four folds increased compared to healthy
individual with marked chain imbalance in β-thal major [3]. Cation-
exchange High performance liquid chromatography (CE-HPLC) is
used for hemoglobin variants determination. In this system, the Hb
variants are pre-defined with; Unique elution/ retention times (the
time elapses from the sample injection to the apex of the elution peak),
peak or curve shapes and peak height / amplitudes (Area). The
currently available HPLC software for Hb variants analysis (Variant
II®, Bio-Rad Laboratories, β Thalassemia Short program), does not
integrate any portion that elute before 0.75 min. Peak that elutes at a
non-predefined / non-Integrated retention time is labeled as unknown
peak. The unknown peaks are identified only by visual analysis of the
chromatography (c-gram). Moreover, the calculated total percentages
of the Hb measured by Variant II® HPLC are not always 100 percent
[7,8]. Separation of hemoglobin variants by HPLC analyzer is due to
the affinity of the hemoglobin cation to the poly aspartic acid-coated
particles of silica contained in a separation column. For separation, the
diluted blood is passed under pressure through the column and then
the eluted fraction passed to detector where the amount of the eluted
fraction is measured and expressed as a peak. Thereafter, the eluted
fraction of the solution is drained under no pressure into the waste
bottle [9,10]. We have noted the occurrence of unknown early-eluting
peaks within the first-minute retention time during high-performance
liquid chromatography (HPLC) analysis of hemoglobin (Hb) in
patients with different clinical phenotypes of β-thal. We noticed the
low-amplitudes or absence of the early-eluting unknown peaks during
HPLC analysis of blood from healthy individual and even in the
presence of other structural Hb variants such as Hb-S. Moreover, the
peak’s amplitudes are comparable with the levels of Hb-F or Hb-A2
and that the retention time of these unknown HPLC peaks is close to
where Hb-H & Hb-Barts eluted during HPLC analysis (Figure 1). Hb
Barts (γ4) and Hb-H elutes from the separation column prior to the
start of integration, and appear as fast-eluting peaks in HPLC. Because
the α-Hb is composed of monomers and dimers of free alpha globin
chain, it could elutes and appear as peaks at early retention time on
HPLC analysis similar to the pattern of Hb-H and Hb-Bart as each of
them is composed of one type of globin chain, alpha, beta & gamma
consequently [11-14]. The currently proposed reasons of the unknown
peaks are: Hb-Bart, Hb-H, altered / acetylated Hb-F in neonate (Hb-
F1), bilirubin and Injection artifacts [7-15]. Recombinant alpha-
hemoglobin stabilizing protein was successfully used to measure the
free alpha-hemoglobin (α-Hb) in hemolysate of patients with β-thal
and healthy individuals [16]. There is lack of biomarker that conveys
diagnostic and / or prognostic values in the management of β-thal of
various clinical phenotypes. Understanding the significances of free α-
Hb was recommended [3,16].
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Figure 1: Illustration of the configurations and amplitudes of the
unknown fast-eluting HPLC peaks. The unknown peaks shows;
higher amplitudes when the level of Hb-F or Hb-A2 % is elevated
(A) compared to their low-magnitudes or absence in the presence
of normal level of Hb-F or Hb-A2 and even in the presence of
structural hemoglobin variants (B and C).
Conclusion
Configuration analysis of the unknown peaks eluted during the
HPLC analysis of hemoglobin for the manifestation of free α-Hb in
patients with β-thal of various clinical phenotypes including Hb-E β-
thalassaemia syndrome needs to be formulated.
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